Comments from Radient's I.R. Department"
Wcoastguy, IMO there are a couple of reasons why they had not yet had the shareholder meeting.
First is the SEC. They had to get their filing up to date and acceptable to the SEC. Then they have to submit another PRE 14A.
One problem. The lenders have not yet agreed to a share conversion so if shareholder approval is required, they don't know how many shares it will be.
Also, the company needs to file an S1 to register the shares so unless the lenders are threatening to take the assets, there is not really that much of a rush.
If you do call them again, you might ask why the CEO stated in a conference call a year ago that they had a new antibody and why are they now saying they don't have one?